APA

Aro J., Ruutu M., Juusela H., Hansson E. & Permi J. (19940224). Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. : Annales chirurgiae et gynaecologiae. Supplementum.

Chicago

Aro J, Ruutu M, Juusela H, Hansson E and Permi J. 19940224. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. : Annales chirurgiae et gynaecologiae. Supplementum.

Harvard

Aro J., Ruutu M., Juusela H., Hansson E. and Permi J. (19940224). Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. : Annales chirurgiae et gynaecologiae. Supplementum.

MLA

Aro J, Ruutu M, Juusela H, Hansson E and Permi J. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. : Annales chirurgiae et gynaecologiae. Supplementum. 19940224.